ContraFect Corp.
Repurposing lysins as antibacterials
This article was originally published in Start Up
Executive Summary
ContraFect Corp., formed in 2008 to develop monoclonal antibodies against bacterial and viral components that do not mutate, is now focused on commercializing a recombinant form of a lysin evolved to target Staphylococcus aureus.